Bright minds biosciences proprietary compound, bmb-201, 5-ht2c/2a mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Bmb-201 demonstrated dose-dependent efficacy in pain models bmb-201 demonstrated similar efficacy to morphine in several pain models new york, oct. 16, 2024 (globe newswire) -- bright minds biosciences inc. (nasdaq: drug), a pioneering company focused on developing highly selective 5-ht2 agonists for the treatment of drug-resistant epilepsy, depression, and other cns disorders, is excited to announce positive data from the preclinical testing of bmb-201 completed with national institute of health pain screening (pspp) program. preclinical pain models included plantar incision and l5/l6 nerve ligation rat models, where the drug candidate was tested along with morphine and gabapentin as positive controls.
DRUG Ratings Summary
DRUG Quant Ranking